Funding for this research was provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Text and Data Mining valid from 2019-03-22
First Online: 22 March 2019
Compliance with Ethical Standards
: This study was supported by research funding from Otsuka Pharmaceutical Development & Commercialization, Inc. to Tufts Medical Center.
: Pei-Jung Lin has served as a consultant for Avanir, Otsuka, and Takeda outside the submitted work. Peter Neumann reports honorarium income from Merck, Bayer, Pacira, Novo Nordisk, Shire, and Amgen, other income from the Congressional Budget Office, Boston Health Economics, Vertex, and Precision Health Economics, and funding support from CEA Registry sponsors outside the submitted work. Myrlene Sanon Aigbogun and Dorothee Oberdhan are employees of Otsuka Pharmaceutical Development & Commercialization, Inc., which provided funding for this research. Tara Lavelle has received consulting fees from Takeda Pharmaceuticals for advice on a cost-effectiveness analysis for Alzheimer’s disease. Brittany D’Cruz and Ashley A. Leech have no conflicts of interest that are directly relevant to the content of this article.
: P-J L, BD’C, PJN, MSA, DO, and TAL provided the study concept and design. P-JL, BD’C, AAL, and TAL were involved in the data acquisition. P-JL, BD’C, AAL, MSA, and TAL drafted the manuscript. All authors participated in the analysis or interpretation of data as well as the preparation and critical revision of the manuscript.